[1] |
ALI AA, ALMUKHTAR SE, ABD KH, et al. The causes and frequency of kidney allograft failure in a low-resource setting: observational data from Iraqi Kurdistan[J]. BMC Nephrol, 2021, 22(1): 272. DOI: 10.1186/s12882-021-02486-9.
|
[2] |
MILLÁN O, ROVIRA J, GUIRADO L, et al. Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation[J]. Clin Immunol, 2021, 229: 108792. DOI: 10.1016/j.clim.2021.108792.
|
[3] |
CHOI J, CHANDRAKER A. Immunologic risk assessment and approach to immunosuppression regimen in kidney transplantation[J]. Clin Lab Med, 2019, 39(4): 643-656. DOI: 10.1016/j.cll.2019.07.010.
|
[4] |
LAN JH, KADATZ M, CHANG DT, et al. Pretransplant calculated panel reactive antibody in the absence of donor-specific antibody and kidney allograft survival[J]. Clin J Am Soc Nephrol, 2021, 16(2): 275-283. DOI: 10.2215/CJN.13640820.
|
[5] |
KEITH DS, VRANIC GM. Approach to the highly sensitized kidney transplant candidate[J]. Clin J Am Soc Nephrol, 2016, 11(4): 684-693. DOI: 10.2215/CJN.05930615.
|
[6] |
SÜSAL C, MORATH C. Virtual PRA replaces traditional PRA: small change but significantly more justice for sensitized patients[J]. Transpl Int, 2015, 28(6): 708-709. DOI: 10.1111/tri.12572.
|
[7] |
HUBER L, LACHMANN N, NIEMANN M, et al. Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients[J]. Transpl Int, 2015, 28(6): 710-719. DOI: 10.1111/tri.12533.
|
[8] |
MALHEIRO J, TAFULO S, DIAS L, et al. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation[J]. Transpl Immunol, 2015, 32(2): 66-71. DOI: 10.1016/j.trim.2015.01.002.
|
[9] |
ALVAREZ-MÁRQUEZ A, AGUILERA I, GENTIL MA, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies[J]. Transplantation, 2009, 87(1): 94-99. DOI: 10.1097/TP.0b013e31818bd790.
|
[10] |
BUTLER CL, HICKEY MJ, JIANG N, et al. Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: from bench to bedside[J]. Am J Transplant, 2020, 20(10): 2768-2780. DOI: 10.1111/ajt.15863.
|
[11] |
TAMBUR AR, CAMPBELL P, CHONG AS, et al. Sensitization in Transplantation: Assessment of Risk (STAR) 2019 working group meeting report[J]. Am J Transplant, 2020, 20(10): 2652-2668. DOI: 10.1111/ajt.15937.
|
[12] |
SENEV A, COEMANS M, LERUT E, et al. Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study[J]. J Am Soc Nephrol, 2020, 31(9): 2193-2204. DOI: 10.1681/ASN.2020010019.
|
[13] |
PHILOGENE MC, AMIN A, ZHOU S, et al. Eplet mismatch analysis and allograft outcome across racially diverse groups in a pediatric transplant cohort: a singlecenter analysis[J]. Pediatr Nephrol, 2020, 35(1): 83-94. DOI: 10.1007/s00467-019-04344-1.
|
[14] |
TAFULO S, MALHEIRO J, SANTOS S, et al. Degree of HLA class Ⅱ eplet mismatch load improves prediction of antibody-mediated rejection in living donor kidney transplantation[J]. Hum Immunol, 2019, 80(12): 966-975. DOI: 10.1016/j.humimm.2019.09.010.
|
[15] |
MALLON DH, KLING C, ROBB M, et al. Predicting humoral alloimmunity from differences in donor and recipient HLA surface electrostatic potential[J]. J Immunol, 2018, 201(12): 3780-3792. DOI: 10.4049/jimmunol.1800683.
|
[16] |
TAMBUR AR, MCDOWELL H, HOD-DVORAI R, et al. The quest to decipher HLA immunogenicity: telling friend from foe[J]. Am J Transplant, 2019, 19(10): 2910- 2925. DOI: 10.1111/ajt.15489.
|
[17] |
ALTHAF MM, EL KOSSI M, JIN JK, et al. Human leukocyte antigen typing and crossmatch: a comprehensive review[J]. World J Transplant, 2017, 7(6): 339-348. DOI: 10.5500/wjt.v7.i6.339.
|
[18] |
KOEFOED-NIELSEN P, MØLLER BK. Donor-specific anti-HLA antibodies by solid phase immunoassays: advantages and technical concerns[J]. Int Rev Immunol, 2019, 38(3): 95-105. DOI: 10.1080/08830185.2018.1525367.
|
[19] |
MORRIS AB, SULLIVAN HC, KRUMMEY SM, et al. Out with the old, in with the new: virtual versus physical crossmatching in the modern era[J]. HLA, 2019, 94(6): 471-481. DOI: 10.1111/tan.13693.
|
[20] |
TAMBUR AR, CAMPBELL P, CLAAS FH, et al. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 working group meeting report[J]. Am J Transplant, 2018, 18(7): 1604-1614. DOI: 10.1111/ajt.14752.
|
[21] |
UBARA Y, KAWAGUCHI T, NAGASAWA T, et al. Kidney biopsy guidebook 2020 in Japan[J]. Clin Exp Nephrol, 2021, 25(4): 325-364. DOI: 10.1007/s10157-020-01986-6.
|
[22] |
SCHINSTOCK CA, COSIO F, CHEUNGPASITPORN W, et al. The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss[J]. Am J Transplant, 2017, 17(6): 1574- 1584. DOI: 10.1111/ajt.14161.
|
[23] |
FU MS, LIM SJ, JALALONMUHALI M, et al. Clinical significance of renal allograft protocol biopsies: a single tertiary center experience in Malaysia[J]. J Transplant, 2019: 9153875. DOI: 10.1155/2019/9153875.
|
[24] |
MUCZYNSKI KA, LECA N, ANDERSON AE, et al. Multicolor flow cytometry and cytokine analysis provides enhanced information on kidney transplant biopsies[J]. Kidney Int Rep, 2018, 3(4): 956-969. DOI: 10.1016/j.ekir.2018.02.012.
|
[25] |
SAWITZKI B, HARDEN PN, REINKE P, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials[J]. Lancet, 2020, 395(10237): 1627-1639. DOI: 10.1016/S0140-6736(20)30167-7.
|
[26] |
BECKETT J, HESTER J, ISSA F, et al. Regulatory B cells in transplantation: roadmaps to clinic[J]. Transpl Int, 2020, 33(11): 1353-1368. DOI: 10.1111/tri.13706.
|
[27] |
ZHANG R. Donor-specific antibodies in kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2018, 13(1): 182-192. DOI: 10.2215/CJN.00700117.
|
[28] |
TIMOFEEVA OA. Donor-specific HLA antibodies as biomarkers of transplant rejection[J]. Clin Lab Med, 2019, 39(1): 45-60. DOI: 10.1016/j.cll.2018.10.007.
|
[29] |
HOURMANT M, CESBRON-GAUTIER A, TERASAKI PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation[J]. J Am Soc Nephrol, 2005, 16(9): 2804-2812. DOI: 10.1681/ASN.2004121130.
|
[30] |
MALHEIRO J, TAFULO S, DIAS L, et al. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation[J]. Transpl Int, 2017, 30(4): 347-359. DOI: 10.1111/tri.12873.
|
[31] |
LEFAUCHEUR C, VIGLIETTI D, BENTLEJEWSKI C, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury[J]. J Am Soc Nephrol, 2016, 27(1): 293-304. DOI: 10.1681/ASN.2014111120.
|
[32] |
RAMPERSAD C, SHAW J, GIBSON IW, et al. Early antibody-mediated kidney transplant rejection associated with anti-vimentin antibodies: a case report[J]. Am J Kidney Dis, 2020, 75(1): 138-143. DOI: 10.1053/j.ajkd.2019.06.010.
|
[33] |
CHOWDHRY M, MAKROO RN, SINGH M, et al. Role of anti-MICA antibodies in graft survival of renal transplant recipients of India[J]. J Immunol Res, 2018: 3434050. DOI: 10.1155/2018/3434050.
|
[34] |
AKGUL SU, OGUZ FS, ÇALIŞKAN Y, et al. The effect of glutathion S-transferase polymoprhisms and antiGSTT1 antibodies on allograft functions in recipients of renal transplant[J]. Transplant Proc, 2012, 44(6): 1679- 1684. DOI: 10.1016/j.transproceed.2012.04.004.
|
[35] |
LEFAUCHEUR C, VIGLIETTI D, BOUATOU Y, et al. Non-HLA agonistic anti-angiotensin Ⅱ type 1 receptor antibodies induce a distinctive phenotype of antibodymediated rejection in kidney transplant recipients[J]. Kidney Int, 2019, 96(1): 189-201. DOI: 10.1016/j.kint.2019.01.030.
|
[36] |
CRESPO M, LLINÀS-MALLOL L, REDONDOPACHÓN D, et al. Non-HLA antibodies and epitope mismatches in kidney transplant recipients with histological antibody-mediated rejection[J]. Front Immunol, 2021, 12: 703457. DOI: 10.3389/fimmu.2021.703457.
|
[37] |
SUTHERLAND SM, LI L, SIGDEL TK, et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients[J]. Kidney Int, 2009, 76(12): 1277-1283. DOI: 10.1038/ki.2009.384.
|
[38] |
BLOOM RD, BROMBERG JS, POGGIO ED, et al. Cellfree DNA and active rejection in kidney allografts[J]. J Am Soc Nephrol, 2017, 28(7): 2221-2232. DOI: 10.1681/ASN.2016091034.
|
[39] |
THONGPRAYOON C, VAITLA P, CRAICI IM, et al. The use of donor-derived cell-free DNA for assessment of allograft rejection and injury status[J]. J Clin Med, 2020, 9(5): 1480. DOI: 10.3390/jcm9051480.
|
[40] |
VEERMAN RE, GÜÇLÜLER AKPINAR G, ELDH M, et al. Immune cell-derived extracellular vesicles - functions and therapeutic applications[J]. Trends Mol Med, 2019, 25(5): 382-394. DOI: 10.1016/j.molmed.2019.02.003.
|
[41] |
BENICHOU G, WANG M, AHRENS K, et al. Extracellular vesicles in allograft rejection and tolerance[J]. Cell Immunol, 2020, 349: 104063. DOI: 10.1016/j.cellimm.2020.104063.
|
[42] |
TAKADA Y, KAMIMURA D, JIANG JJ, et al. Increased urinary exosomal SYT17 levels in chronic active antibody-mediated rejection after kidney transplantation via the IL-6 amplifier[J]. Int Immunol, 2020, 32(10): 653- 662. DOI: 10.1093/intimm/dxaa032.
|
[43] |
MATZ M, HEINRICH F, LORKOWSKI C, et al. MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection[J]. PLoS One, 2018, 13(8): e0201925. DOI: 10.1371/journal.pone.0201925.
|
[44] |
NARIMAN-SALEH-FAM Z, BASTAMI M, ARDALAN M, et al. Cell-free microRNA-148a is associated with renal allograft dysfunction: implication for biomarker discovery[J]. J Cell Biochem, 2019, 120(4): 5737-5746. DOI: 10.1002/jcb.27860.
|
[45] |
VAN LOON E, GAZUT S, YAZDANI S, et al. Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: a multicentre, prospective study[J]. EBioMedicine, 2019, 46: 463-472. DOI: 10.1016/j.ebiom.2019.07.028.
|
[46] |
DIEBOLDER CA, BEURSKENS FJ, DE JONG RN, et al. Complement is activated by IgG hexamers assembled at the cell surface[J]. Science, 2014, 343(6176): 1260- 1263. DOI: 10.1126/science.1248943.
|
[47] |
LAN JH, TINCKAM K. Clinical utility of complement dependent assays in kidney transplantation[J]. Transplantation, 2018, 102(1S Suppl 1): S14-S22. DOI: 10.1097/TP.0000000000001819.
|
[48] |
WEITZNER BD, DUNBRACK RL JR, GRAY JJ. The origin of CDR H3 structural diversity[J]. Structure, 2015, 23(2): 302-311. DOI: 10.1016/j.str.2014.11.010.
|